McKesson Corporation vs Health Care Select Sector SPDR Fund — how do they compare? McKesson Corporation trades at $937.1 (market cap $108.46B), while Health Care Select Sector SPDR Fund trades at $170.75 (market cap $43.48B). The key difference: McKesson Corporation is far larger — about 2.5× Health Care Select Sector SPDR Fund's market cap, and McKesson Corporation pays a 0.4% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| MCK | XLV | |
|---|---|---|
Market Cap | $108.46B | $43.48B |
Volume | 712,607 | 11,121,431 |
Sector | Health | — |
52-Week High | $995.69 | $175.68 |
52-Week Low | $725.17 | $141.95 |
Typical Hold Time | 74 Days | 100 Days |
Enterprise Value | $115.00B | — |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $938.84, up 3.13% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
The outlook is positive with 81% analyst buy ratings and a $956.43 consensus price target. Key risks include margin pressure from drug pricing policies and high current liabilities of $61.60B. The stock's valuation at 24.95x P/E appears reasonable given earnings growth projections, but investors should monitor debt levels and regulatory developments in healthcare distribution.
XLV trades at $170.81, up 1.18% with a bearish technical signal from moving averages. The ETF's low 0.08% expense ratio and healthcare sector diversification provide defensive positioning amid market volatility. Recent options activity shows increased put volume, indicating some investor caution despite healthcare's traditional defensive characteristics during economic uncertainty.
Healthcare sector ETFs like XLV offer defensive exposure with potential upside from demographic trends and innovation. Key risks include political volatility around healthcare policy and concentration in large-cap US stocks. The ETF's cost efficiency and sector positioning make it attractive for long-term investors seeking healthcare exposure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →